Lipocine announces settlement with clarus therapeutics

Salt lake city, july 14, 2021 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that it has entered into a global settlement and license agreement with clarus therapeutics inc. ("clarus") to resolve all outstanding claims in the on-going intellectual property litigation between the two companies as well as the on-going interference proceeding between the two companies. under the terms of the settlement announced today, lipocine and clarus have agreed to dismiss the lipocine inc. v clarus therapeutics, inc., no 19-cv-622 (wcb) litigation presently pending in the u.s. district court for the district of delaware.
LPCN Ratings Summary
LPCN Quant Ranking